Vieworks Unveils Digital Pathology Scanner LUCEON at ECP 2024
ANYANG-SI, South Korea, Sept. 6, 2024 /PRNewswire/ -- Vieworks, a leading name in bioimaging solutions, is to set a new standard in the digital pathology field with the launch of its high-speed slide scanner LUCEON 510. Vieworks will be making its debut as a digital pathology solution provider at the upcoming European Congress of Pathology (ECP) 2024, one...
City of Riyadh Gears Up to Unveil the Future of Healthcare: Global Health Exhibition
Kingdom of Saudi Arabia to host Global Health Exhibition (21-23 October 2024), a major international event at a venue double the size with over 100,000 attendees and 1,200 exhibiting companies and brands to join in Malham, Riyadh Event will host 500+ expert speakers across multiple healthcare disciplines showcasing frontier-pushing medical advancements alongside over 100 hours of accredited CME opportunities for...
Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024)
HANGZHOU, China and SAN FRANCISCO, Sept. 6, 2024 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide (XW003) in patients with type II diabetes mellitus and from a...
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies
HONG KONG, Sept. 6, 2024 /PRNewswire/ -- Akeso, Inc. (9926.HK) will showcase promising results from 13 clinical studies on its internally developed PD-1/CTLA-4 bispecific antibody cadonilimab, PD-1/VEGF bispecific antibody ivonescimab, next-generation CD47 monoclonal antibody ligufalimab, and commercially available PD-1 monoclonal antibody penpulimab at the ESMO Congress 2024 from September 13th to 17th (CEST). These studies span advanced colorectal...
Baird Medical and ExcelFin Acquisition Corp Announce Effectiveness of Registration Statement
FORT MILL, S.C., Sept. 6, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China, and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced that Baird Medical Investment Holdings Limited's ("PubCo") registration statement on Form F-4 (the "Registration...
A Small Step towards a Big Mission! World’s First! UltraDx Received First Clinical Approval of Single-Molecule Analyzer, in China
SHANGHAI, Sept. 5, 2024 /PRNewswire/ -- UltraDx Bio is proud to announce that its flagship product, the UD-X™ Fully Automated Single-Molecule Array Fluorescence Immunoassay Analyzer, has received its first clinical registration approval in China. This groundbreaking achievement is now officially listed on the National Medical Products Administration (NMPA) website (Registration Certificate No.: JXZZ 20242220334) and marks a significant milestone...
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms Transaction proceeds to accelerate three most advanced clinical programs for the adeno-associated virus (AAV)-based gene therapy candidates The combined company to have an implied...
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study
HANGZHOU, China, Sept. 5, 2024 /PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house developed next-generation balloon-expandable dry-tissue transcatheter aortic valve replacement (TAVR) system, Venus-Vitae, successfully completed two inaugural implantations as part of its global multicenter pivotal trial, Venus-Vitae SMART-ALIGN, at Prince of...
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 5, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS). Sanbexin sublingual tablets is the first...
The Vietnam Small Animal Veterinary Association (VSAVA) and South Korea’s NEL Animal Medical Foundation have joined forces to strengthen international cooperation in veterinary medicine
HO CHI MINH, Vietnam, Sept. 5, 2024 /PRNewswire/ -- Saigon Ventures Co., Ltd. facilitated the signing of a Memorandum of Understanding (MOU) between South Korea's NEL Animal Medical Foundation (formerly NEL Animal Medical Center) and the Vietnam Small Animal Veterinary Association (VSAVA) to promote industry-academia collaboration and international exchange. (left - right) Nong Lam University, Professor, Minh Võ Dương,...
